Xolair 150 MG/ML syringeml
Ended Awarded Last action
- Contract number
- SPE2DR26FFBN0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $11,844
Award facts
- Contract value 100% obligated
- $11,844.20 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $11,844.20 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Xolair 150 mg/ml syringes. This firm fixed-price delivery order, issued on November 24, 2025, with an ultimate completion date of December 16, 2025, carries no set-aside designation, demonstrating DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The award was funded by the Defense Logistics Agency and represents a continuation of the company's substantial pharmaceutical supply activity supporting Department of Defense medical operations.
This delivery order was issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) designated SPE2DR under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative. The parent IDC, awarded November 13, 2025, carries a $499.9 billion ceiling value and extends through December 31, 2036, positioning DMS Pharmaceutical Group as a critical regional prime vendor contractor within the broader $30.3 billion PPV-G GEN V acquisition strategy. The contract structure enables the Defense Logistics Agency to issue firm fixed-price delivery orders for comprehensive pharmaceutical products—including branded and generic prescription drugs, biologics, and medical consumables—to support recurring medical supply requirements for military healthcare facilities worldwide. DMS Pharmaceutical Group's established performance record demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system globally.
Quick answers
Who was awarded contract SPE2DR26FFBN0?
SPE2DR26FFBN0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 24, 2025.
How much is contract SPE2DR26FFBN0 worth?
The government has obligated $11,844 on SPE2DR26FFBN0.
Is contract SPE2DR26FFBN0 an order under another contract?
Yes. SPE2DR26FFBN0 is a delivery order under SPE2DR25D9239, an indefinite delivery contract.
Was contract SPE2DR26FFBN0 competed?
The extent of competition for SPE2DR26FFBN0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award